Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.31 |
| ▸ | SLC2A3 | P11169 | 2/20 | 0.31 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23976139 | 0.93 | HDAC1 (0.37) | MEN1POLBKMT2AHDAC1HDAC8 | |
| SCHEMBL23976638 | 0.91 | HDAC1 (0.36) | MEN1POLBKMT2AHDAC1HDAC8 | |
| SCHEMBL30118766 | 0.90 | SYK (0.38) | MEN1POLBKMT2AHDAC1HDAC8 | |
| SCHEMBL23975777 | 0.90 | SYK (0.38) | MEN1POLBKMT2AHDAC1HDAC8 | |
| SCHEMBL26228707 | 0.90 | HDAC1 (0.38) | MEN1POLBKMT2AHDAC1HDAC8 | |
| SCHEMBL23976130 | 0.90 | HDAC1 (0.35) | MEN1POLBKMT2AHDAC1HDAC8 | |
| SCHEMBL30118866 | 0.90 | HDAC1 (0.35) | MEN1POLBKMT2AHDAC1HDAC8 | |
| SCHEMBL23975593 | 0.90 | HDAC1 (0.37) | MEN1POLBKMT2AHDAC1HDAC8 | |
| SCHEMBL30118823 | 0.90 | HDAC1 (0.39) | MEN1POLBKMT2AHDAC1HDAC8 | |
| SCHEMBL23975924 | 0.90 | HDAC1 (0.39) | MEN1POLBKMT2AHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | MEN1 2863/4885POLB 355/4885KMT2A 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.